Roche introduces a digital PCR system in the fight against cancer and other diseases

SWITZERLAND- The first digital polymerase chain reaction (PCR) machine from Roche has been made available for purchase, according to Swiss Pharma.

This next-generation system is made to precisely measure minute amounts of a variety of DNA and RNA targets that are generally undetectable by traditional PCR techniques. It also detects illness.

Clinical researchers will be able to separate DNA and RNA from a clinical sample that has previously been extracted into as many as 100,000 tiny individual reactions using the Digital LightCycler System.

The system can then do PCR and analyze the findings with extremely complex data.

“Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient,” said Thomas Schinecker, CEO of Roche Diagnostics.

“The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions.”

The technique gives researchers additional chances in fields like oncology and infectious illness that regular PCR technology cannot.

This includes identifying extremely rare targets, precisely estimating the amount of target DNA or RNA present at the molecular level, and performing additional high-precision analyses.

With plans to expand into more nations soon, the system will be made available in 15 countries by the year 2022. It will have an FDA 510(k) exemption and a CE mark.

Over the course of several decades, Roche has significantly aided in the development and advancement of PCR technology.

Roche recognized the promise of PCR in 1991 and made investments to advance the field for use in molecular diagnostics, which seeks to identify infections and genetic code alterations that cause disease.

The Roche range of widely accessible PCR solutions is complemented by the distinctive features of the Digital LightCycler System.

The introduction of this new technology expands on the company’s founding legacy in PCR and contributes to the PCR ecosystem.

Roche will supply both methods, giving the medical industry a range of molecular options.

With plans to expand into more nations soon, the system will be made available in 15 countries by the year 2022. It will have an FDA 510(k) exemption and a CE mark.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE